| ObjectiveThis study aimed to observe stable COPD during treatment, CAT and BODE and its four constituent elements of relevance, and grouped according to2011GOLD guide each group after comprehensive assessment of CAT and BODE and four constituent elements of relevance. Also observed after treatment with simvastatin on the impact of both.Materials and Methods1.A study population selected East County, Shandong Province People’s Hospital from October2011to March2013inpatient and outpatient follow-up of patients with stable COPD154cases,118cases were male,76.6%, female36cases, accounting for23.4%. The youngest43years old, maximum89years, mean age66.71±9.49years old., According to2011GOLD guide will conduct its assessment of symptoms and risk models are divided into A, B, C, D groups, A group of30cases, B group31cases, C group33cases, D group,60patients were randomly divided into two groups: oral simvastatin treatment group36cases,38cases of oral placebo control group. All subjects were informed of the trial and voluntarily participate in the trial. All patients were consistent with COPD treatment guidelines (2007Revision) established diagnostic criteria for COPD. At least4weeks prior to study entry unused antibiotics or oral corticosteroids. Two group sex and age, FEV1, and smoking history was no significant difference. 2.Selected154cases for patients with COPD CAT and BODE score, and in accordance with stable COPD guidelines formal treatment three months, CAT and BODE score again, while76cases were randomly selected set divided into two groups, the treatment group36cases, the patient every late oral simvastatin20mg, for12weeks, compared to38cases of oral placebo. CAT and BODE compare before and after treatment changes.3.All data were analyzed using statistical software SPSS16.0The results were expressed as mean±standard deviation (xχ±s) said that under the circumstances, the line two-sample t-test, correlation analysis using Pearson correlation analysis, and qualitative data for the Spearman rank correlation, difference analysis of multivariate data T test comparison, qualitative data is applied chi-square test, P<0.05was considered statistically significant.Results1..CAT score before treatment and the BODE index, was positively associated with the degree of difficulty breathing (r value were0.573,0.644, P values<0.0001,<0.0001), respectively and negatively correlated with FEV1%,6MWDS (r value of0.229and0.550respectively, P value is0.004,<0.0001), not related with BMI (r value is0.067, P value is0.412).MMRC score was positively correlated with BODE index before treatment, and negatively correlated with FEVI%(r value were0.730,0.302, respectively P values<0.0001,0.0001).CAT score after treatment with BODE index score, was positively associated with the degree of difficulty breathing (r value were0.581,0.681, P values<0.0001,<0.0001), respectively and negatively correlated with FEV1%,6MWDS (r value of0.382and0.528respectively, P values<0.0001,<0.0001), not related with BMI (r value is0.132, P value is0.103).MMRC score after treatment with BODE index scores were positively correlated, and negatively correlated with FEVI%(r value were0.627,0.317, P<0.0001, respectiely, in,<0.0001).2.Group A CAT score was positively related with FEV1%before treatment (P value for r value was0.402,0.0279), and the BODE index score, degree of difficulty in breathing,6MWDS, were not associated with BMI (r value respectively0.061,0.231, 0.058,0.231, P values were0.7485,0.2200,0.7603,0.1840).Group A mMRC score before treatment and the BODE index score, FEVI%unrelated (r value of0.016and0.195respectively, P values were0.946,0.410).Group A CAT score after treatment and were positively associated with the degree of difficulty in breathing (P value for r value was0.396,0.0303), and the BODE index score, FEVI%,6MWDS, were not associated with BMI (r value respectively0.206,0.057,0.123,0.057, P values were0.2739,0.7651,0.5163,0.7795).MMRC score after treatment group A with BODE index score, FEVI%unrelated (r value of0.074and0.009respectively, P values were0.755,0.968).3.Group B CAT score before treatment and the BODE index score, was positively associated with the degree of difficulty breathing (r value of0.411,0.411, P value is0.0217,0.0217), and negatively correlated with FEVI%,6MWDS (r value is0.180,0.464, P value is0.3320,0.3320), not related with BMI (P value for r value was0.069,0.7121).Group B mMRC score before treatment and BODE index scores were positively correlated, FEVI%not related (r value of0.875and0.261respectively, respectively P values<0.001,0.348).Group B after treatment the CAT score and BODE index score, was positively associated with the degree of difficulty breathing (r value of0.382,0.382, P value is0.0342,0.0342), with FEVI%,6MWDS, were not associated with BMI (r value respectively0.235,0.220,0.280, P values were0.2033,0.2339,0.1271).Group B after treatment mMRC score was positively correlated with BODE index score, FEVI%,(r value were0.830,0.800, P<0.001, respectiely, in,<0.001).4.Group C CAT score before treatment and the BODE index score, was positively associated with the degree of difficulty breathing (r value were0.474,0.497, P values were0.0053,0.0032), and negatively correlated with BMI,6MWDS (r value of0.323and0.491respectively, P values were0.0666,0.0038), with FEVI%unrelated (r value is0.099, P value is0.5857).Group C mMRC score before treatment and the BODE index scores were positively correlated, FEVI%not related (r value of0.701and0.271respectively, respectively P values<0.001,0.128).Group C CAT score after treatment with BODE index score, was positively associated with the degree of difficulty breathing (r value were0.460,0.722, P values were0.0071,<0.0001), and negatively correlated with FEV1%,6MWDS, BMI (r value respectively0.353,0.514,0.247, P values were0.0440,0.0022,0.1658).Group C mMRC score after treatment with BODE index scores were positively correlated, FEVI%not related (r value were0.605,0.337, respectively P values<0.001,0.055).5.Group D CAT score before treatment and the BODE index score, was positively associated with the degree of difficulty breathing (r value were0.433,0.580, P values were0.0005,<0.0001), and negatively correlated with6MWDS (r value is0.333, P value is0.0093), and FEVI%, were not associated with BMI (r value were0.0135,0.140, P value is0.9184,0.9184).Group D mMRC score before treatment and the BODE index scores were positively correlated, and negatively correlated with FEVI%(r value of0.754and0.256respectively, respectively P values<0.001,0.149).Group D CAT score after treatment with BODE index score, was positively associated with the degree of difficulty breathing (r value were0.431,0.592, P values were0.0006,<0.0001), and negatively correlated with6MWDS (r value is0.473, P value is0.0001), and FEVI%, were not associated with BMI (r value were0.096,0.040, P value is0.4647,0.4647).Group D mMRC score after treatment with BODE index scores were positively correlated, FEVI%not related (r value were0.557,0.036, respectively P values<0.001,0.783).6.Difference before and after simvastatin treatment group comparison: the CAT has a significant statistical significance (P value is0.040), FEVI%does not have significant statistical significance (P value is0.422), BMI has no significant statistical significance (P value is0.978),6MWDS has no significant statistical significance (P value is0.351), BODE index has no significant statistical significance (P value is0.538), MMRC has no significant statistical significance (P value is0.1024)..Conclusions1.Assessment in the process of stabilization treatment of COPD patients with COPD, for relatively heavy patients’ CAT, B, C, D group mMRC can take the place of BODE index, for the treatment of patients with mild group A CAT, mMRC BODE index can not be replaced.2.BODE index for the four constituent elements, relatively heavy in condition B, C, D group of patients CAT can replace MMRC.3.In the process of COPD stabilization treatment application simvastatin, can improve the level of the CAT. |
PDF Full Text Request